8 am

CMSC - ACTRIMS Donald Paty Memorial Lecture

Pros and cons of stem cell therapy
Neil Scolding, PhD, FRCP- University of Bristol

9 - 10:30 am

Session 1: Cell Replacement and Repair
Moderators: Mark Freedman, MD, and Emmanuelle Waubant, MD, PhD

9 am

Neural stem cells as instructors of repair mechanisms
Stefano Pluchino, MD, PhD - IRCCS San Raffaele

9:30 am

Stimulation of endogenous repair
Tanja Kuhlmann, MD - University Hospital Muenster

10 am

Roundtable Discussion/Q&A

10:15 am

Coffee Break

10:30 am - 12 pm

Session 2: Basic and Clinical Issues in Multiple Sclerosis Research
Moderators: Christopher Bever, MD, MBA, and Peter Calabresi, MD

10:30 am

Oral teriflunomide added to interferon-beta in relapsing multiple sclerosis patients: 1-year safety and efficacy results
Mark S. Freedman, MD—The Ottawa Hospital

10:45 am

Quantitative MRI characteristics of pediatric multiple sclerosis
Tanuja Chitnis, MD—Massachusetts General Hospital, Boston

11 am

Noninvasive differentiation of co-existing inflammation, axonal injury, and demyelination in the mouse corpus callosum
Yong Wang, PhD—Washington University School of Medicine, St. Louis

11:15 am

Regulation of the mode of t lymphocyte migration through the choroid plexus epithelium by epithelial v-like antigen
Michael Carrithers, MD, PhD—University of Wisconsin-Madison

11:30am

Cell type-specific responses to IFN-beta: implications for understanding the mechanism of IFN-beta therapy in multiple sclerosis
Anette H. H. van Boxel-Dezaire, PhD—Cleveland Clinic Foundation

11:45 am

Improving the recognition and management of mental health problems in persons with multiple sclerosis
David Rintell, EdD—Partners Multiple Sclerosis Center, Boston

12 - 1 pm

Lunch

1 - 2 pm

Poster Session with Authors Present

2 - 3:30 pm

Session 3: Risk Management
Moderators: Aaron Miller, MD, and Jerry Wolinsky, MD

2 pm

Risk management: an FDA perspective
Russell Katz, MD - US Food and Drug Administration

2:30 pm

Balancing benefit and risk from the patient's perspective
Michael Kattan, PhD - Cleveland Clinic

3 pm

Risk perception about progressive multifocal leukoencephalopathy in natalizumab-treated patients and their neurologists
Sascha Köpke, PhD—University of Hamburg

3:15 pm

Roundtable Discussion/Q&A

3:30 pm

Coffee Break

3:45 - 5 pm

Session 4: Complications of Potent Immunosuppressive Agents in MS
Moderators: Jeffrey Cohen, MD, and Robert Naismith, MD

3:45 pm

Potent immunomodulation in MS: promise and problems (opportunistic infections, malignancies, autoimmunity)
Richard Ransohoff, MD- Cleveland Clinic

4:15 pm

Update: clinical features of PML
David Clifford, MD- Washington University School of Medicine, St. Louis

4:45 pm

Roundtable Discussion/Q&A

5 pm

Closing Remarks